$XLRN ACCELERON PHARMA INC Insider Trading Week 11/2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ACCELERON PHARMA INC in week 11/2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Grant | A | 0.00 | 1,250 | 0 | 5,250 | 4 K to 5.3 K (+31.25 %) |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | POPS RICHARD F | Director | Grant | A | 0.00 | 1,250 | 0 | 30,000 | 28.8 K to 30 K (+4.35 %) |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Grant | A | 0.00 | 1,250 | 0 | 1,250 | 0 to 1.3 K |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | A | 30.17 | 3,272 | 98,716 | 3,272 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Grant | A | 0.00 | 545 | 0 | 545 | 0 to 545 |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Maniatis Tom | Director | Grant | A | 0.00 | 1,250 | 0 | 115,481 | 114.2 K to 115.5 K (+1.09 %) |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Kearney Terrence C | Director | Grant | A | 0.00 | 1,250 | 0 | 1,250 | 0 to 1.3 K |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Grant | A | 0.00 | 1,250 | 0 | 1,250 | 0 to 1.3 K |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 30.17 | 7,500 | 226,275 | 7,500 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Grant | A | 0.00 | 1,250 | 0 | 1,250 | 0 to 1.3 K |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Option Exercise | A | 30.17 | 41,300 | 1,246,021 | 41,300 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | SVP & Chief Scienti ... | Grant | A | 0.00 | 6,900 | 0 | 95,327 | 88.4 K to 95.3 K (+7.80 %) |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Option Exercise | A | 30.17 | 46,300 | 1,396,871 | 46,300 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP, Bus. Dev., GC ... | Grant | A | 0.00 | 7,900 | 0 | 62,423 | 54.5 K to 62.4 K (+14.49 %) |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | A | 30.17 | 41,300 | 1,246,021 | 41,300 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Grant | A | 0.00 | 6,900 | 0 | 77,800 | 70.9 K to 77.8 K (+9.73 %) |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | A | 30.17 | 47,300 | 1,427,041 | 47,300 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Grant | A | 0.00 | 7,900 | 0 | 104,400 | 96.5 K to 104.4 K (+8.19 %) |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | A | 30.17 | 47,300 | 1,427,041 | 47,300 | |
| Mar 14 2017 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Grant | A | 0.00 | 7,900 | 0 | 136,977 | 144.9 K to 137 K (-5.45 %) |